Rhythm Pharmaceuticals Inc RYTM:NASDAQ

Last Price$18.25NASDAQ Closing Price as of 4:00PM ET 1/28/20

Today's Change+0.70(3.99%)
Bid (Size)$18.23 (19)
Ask (Size)$18.24 (21)
Day Low / High$17.41 - 18.33
Volume450.5 K

View Biotechnology IndustryPeer Comparison as of 01/28/2020


Rhythm Pharmaceuticals Inc ( NASDAQ )

Price: $18.25
Change: +0.70 (3.99%)
Volume: 450.5 K
4:00PM ET 1/28/2020

Stoke Therapeutics Inc ( NASDAQ )

Price: $23.58
Change: +0.16 (0.68%)
Volume: 72.8 K
3:59PM ET 1/28/2020

Twist Bioscience Corp ( NASDAQ )

Price: $23.87
Change: +0.87 (3.78%)
Volume: 336.5 K
4:00PM ET 1/28/2020

ZIOPHARM Oncology Inc ( NASDAQ )

Price: $4.38
Change: +0.08 (1.86%)
Volume: 895.9 K
3:59PM ET 1/28/2020

Cara Therapeutics Inc ( NASDAQ )

Price: $16.21
Change: +0.10 (0.62%)
Volume: 307.8 K
4:00PM ET 1/28/2020

Read more news Recent News

Insider Trends: Insider at Rhythm Pharmaceuticals Reports Option Conversion Amid 90-Day Selling Trend
4:03PM ET 1/10/2020 MT Newswires

Dr Keith Michael Gottesdiener, Director and CEO & President, exercised options for 33,072 shares in Rhythm Pharmaceuticals (RYTM) for $151,800 on Jan 08,...

Analyst Actions: Goldman Sachs Initiates Coverage on Rhythm Pharmaceuticals With Sell Rating, $18 Price Target
8:01AM ET 1/08/2020 MT Newswires

Rhythm Pharmaceuticals' (RYTM) average rating among analysts is a buy, with an average price target of $39. Price: 21.42, Change: -0.92, Percent Change:...

Rhythm Pharma CEO Gottesdiener Plans to Step Down, Company Has Enough Funds Until End of 2021
4:34PM ET 1/06/2020 MT Newswires

Rhythm Pharmaceuticals (RYTM) said on Monday Keith Gottesdiener plans to step down as CEO following the completion of its new drug application of...

Insider Trends: 90-Day Insider Selling Trend Prolonged at Rhythm Pharmaceuticals
4:27PM ET 12/13/2019 MT Newswires

Todd Foley, Director, on Dec 11, 2019, sold 17,362 shares in Rhythm Pharmaceuticals (RYTM) for $435,992. Foley, subsequent to the transactions disclosed...

Company Profile

Business DescriptionRhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA. View company web site for more details
Address222 Berkeley Street
Boston, Massachusetts 02116
Number of Employees54
Recent SEC Filing01/28/2020SC 13G
President, Chief Executive Officer & DirectorKeith M. Gottesdiener
Chief Financial Officer & TreasurerHunter C. Smith
Chief Medical OfficerMurray W. Stewart
Chief Commercial OfficerNithya Desikan

Company Highlights

Price Open$17.67
Previous Close$17.55
52 Week Range$17.26 - 31.94
Market Capitalization$801.6 M
Shares Outstanding43.9 M
SectorHealth Technology
Next Earnings Announcement03/13/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.87
Beta vs. S&P 500N/A
Net Profit MarginN/A
Return on Equity-66.86%

Analyst Ratings as of 01/07/2020

Consensus RecommendationConsensus Icon
Powered by Factset